Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutetinib in Locally Advanced or Metastatic NSCLC With Uncommon EGFR Mutations
NCT06010329Phase 2Recruiting
- Sponsor
- SuZhou Teligene
- Start
- Dec 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sutetinib in non-small cell lung cancer (NSCLC), sponsored by SuZhou Teligene. Started Dec 2023; status: recruiting.
02
Drugs
sutetinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06010329.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06010329.